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Introduction
Tissue fibrosis is a major cause of human morbidity and mortality 
worldwide (1, 2). TGF-β1 signaling through its heterotetrameric 
receptor complex of 2 receptor types, TβRII and TβRI, is a well-
known driver of collagen expression and tissue accumulation 
important to wound repair (3). Exaggerated TGF-β1 signaling is 
also strongly implicated in numerous fibrotic diseases, including 
those involving liver, heart, and lung (4–7). For example, approx-
imately 80% of the upregulated genes in lungs of patients with 
idiopathic pulmonary fibrosis are reported to be direct or indirect 
TGF-β1 target genes (8). Pathological collagen accumulation, and 
its promoting effects on tissue stiffness, are also strongly impli-
cated in cancer progression (9–11). TGF-β1 signaling is both an 
initiator and a driver of tissue stiffness because accumulation of 
collagen and other matrix proteins promotes integrin-dependent 
latent TGF-β1 activation and further extracellular matrix deposi-
tion (12). Enhanced stiffness is thought to promote tumor cell β1 
integrin activation, leading to more invasive tumor phenotypes 
and metastasis, consistent with the strong correlation of TGF-β1 
signaling with poor cancer prognosis (9, 13, 14). For these and oth-
er reasons there has been much interest in TGF-β1 signaling as a 
therapeutic target (15–17).
Although attractive as a target, the critical roles of TGF-β1 in 
suppressing inflammation and epithelial proliferation give pause 
to the idea of global inhibition of TGF-β1 signaling (18). Indeed, 
systemic inhibition of TGF-β1 can lead to the development of 
squamous skin tumors and autoreactive immunity (18–21). In 
addition, chronic administration of several small-molecule inhib-
itors of TGF-β1 receptor (TβR) kinases has led to enhanced skin 
and colonic inflammation and abnormalities in cardiac valves 
(22, 23). To minimize adverse consequences, an approach of 
blocking TGF-β1 activation in specific cell types using the unique 
pathway of αvβ6-dependent latent TGF-β1 activation has devel-
oped and is currently in clinical trial (24). But this integrin is pri-
marily expressed in epithelia of lung, kidney, and skin (25). In 
an attempt to develop a more circumscribed inhibitor of TGF-β1 
signaling centered on suppression of collagen accumulation, we 
undertook a high-throughput, image-based phenotypic screen 
of small molecules that could block TGF-β1–induced epithelial- 
mesenchymal transition (EMT) in vitro but not directly inhibit TβRI 
kinase itself. We identified compounds of the ellagitannin and 
catechin families that met these criteria and then explored the 
underlying mechanisms, ultimately revealing a novel approach to 
fibroblast-selective inhibition of TGF-β1 signaling.
Results
Phenotypic screen identifies small molecules with antifibrotic activity in 
vivo. We took advantage of the dramatic phenotypic switch in A549 
lung adenocarcinoma cells upon TGF-β1 stimulation resulting in 
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determinants of TGF-β1–induced EMT suppression in A549 cells 
by other polyphenol family members and found that only polyphe-
nols with at least 1 trihydroxyphenolic motif in their primary struc-
ture inhibited Snail1 expression and their potency of inhibition 
correlated with the number of trihydroxyphenolic units (Supple-
mental Figure 1, B–D). This point is best illustrated by a comparison 
of epicatechin (EC) and epigallocatechin (EGC), which are struc-
loss of E-cadherin expression and induction of fibronectin (26). 
Several small-molecule libraries totaling approximately 40,000 
compounds composed of both diverse and bioactive compounds 
were screened. We identified ellagic acid (EA) as one compound 
meeting our criteria (Figure 1, A–C, and Supplemental Figure 1A; 
supplemental material available online with this article; https://
doi.org/10.1172/JCI94624DS1). We next examined the structural 
Figure 1. EA and corilagin inhibit TGF-β1–dependent EMT and attenuate bleomycin-induced fibrogenesis. (A) Structure of EA. (B) Immunofluorescence 
of TGF-β1–stimulated A549 cells treated with DMSO, SB431542 (SB), or EA. Green, E-cadherin; orange, fibronectin; blue, DAPI. Scale bars: 500 μm. Each 
assay was performed in triplicate. (C) A549 cells were treated with EA (1 μM) and TGF-β1 for 1.5 hours and lysates immunoblotted for p-Smad2, Smad2, 
and β-actin. Repeat = 3. (D) EA dosing and treatment in lung fibrosis model. EA and control (ctl) chow were given to mice for 21 days. Osmotic pumps with 
EA or PBS were implanted on mice for 7 days at day 10 after bleomycin. (E) Hydroxyproline analysis of lung tissues from mice given saline ctl chow (n = 4), 
saline EA chow (n = 4), bleomycin ctl chow (n = 10), and bleomycin EA chow (n = 10). Data represent mean ± SD. (F) Masson’s trichrome staining of lung 
sections from ctl or EA pump–treated mice 17 days after bleomycin. Mosaic images (×4) covering whole lung section are shown. (G) Structure of corilagin. 
(H) A549 cells stimulated with TGF-β1 were treated with corilagin (0–5 μM) for 48 hours and lysates blotted for fibronectin, E-cadherin, Snail1, and β-actin. 
Repeat = 3. (I) Corilagin dosing and treatment in lung fibrosis model. Vehicle or corilagin was given to mice by daily gavage starting from day 10 after bleo-
mycin for 11 days. (J) Hydroxyproline analysis of lung tissues from mice treated with saline vehicle (n = 7), saline corilagin (n = 7), bleomycin vehicle (n = 9), 
and bleomycin corilagin (n = 9). Data represent mean ± SD. (K) Whole lung lysates from mice given saline vehicle (n = 4), saline corilagin (n = 4), bleomycin 
vehicle (n = 5), and bleomycin corilagin (n = 5) were blotted for fibronectin, collagen I, Snail1, β-actin, p-Smad3, and total Smad3. Quantification of bands 
normalized to β-actin is expressed as mean ± SD. Data in E, J, and K were analyzed by 1-way ANOVA with a Tukey post hoc test.
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of lysine primary amines (refs. 33, 34, and Figure 3A). The catalytic 
site quinone oxidizes the primary amines of collagen lysine (Lys) and 
hydroxylysine (Hyl) residues, releasing the respective aldehydes, 
Lysald and Hylald, creating an intermediate aminophenol followed by 
release of H2O2 and NH3, completing the LTQ cycle. Lysald and Hylald 
in monomeric collagens then undergo a series of spontaneous con-
densation reactions that result in the formation of intra- and intermo-
lecular covalent collagen cross-links (35).
We first established an assay of collagen cross-linking induced 
by recombinant LOXL2 (36, 37) and found that corilagin and all 
other trihydroxyphenolics tested prevented cross-linking (IC50 = 10 
nM; Supplemental Figure 3, A–C) whereas an inhibitor of TGF-β1 
signaling (SB431542) and an antioxidant (N-acetylcysteine) had 
no effect (Figure 3B). LOXL2 enzymatic activity toward a model 
substrate was assessed monitoring H2O2 release. Corilagin blocked 
this activity with an IC50 of approximately 50 nM (Figure 3C). 
LOXL2-induced stabilization of Snail1 protein was also blocked by 
corilagin (Figure 3D). To test the possibility that the putative anti-
oxidant activity of trihydrophenolics could either account for the 
observed inhibition of TGF-β1 signaling (38) or directly neutralize 
H2O2 in our LOXL2 enzyme assay, we defined the concentrations 
of corilagin that neutralized H2O2 activity in vitro (Supplemen-
tal Figure 4). We observed no inhibition of H2O2 interaction with 
a reporter substrate by corilagin at ≤10 μM, whereas vitamin C 
neutralized H2O2 at submicromolar concentrations, confirming 
that direct antioxidant scavenging activity could not account for 
our corilagin findings.
To assess inhibition of LOXL2 activity in vivo, we performed 
biochemical analyses of collagens obtained from primary 344SQ 
tumors of mice treated with EA or control chow (refs. 35, 39, and 
Figure 2A). Accumulation of cross-links including 2 reducible cross-
links, HLNL and DHLNL, and a nonreducible, mature cross-link, 
deoxypyridinoline (DPD), was all significantly decreased in prima-
ry tumors of mice fed EA chow, consistent with the altered collagen 
organization in the primary tumors demonstrated by quantitative 
analysis of second-harmonic generation (Table 2 and Figure 2I), 
and confirming inhibition of cross-linking activity by trihydroxy-
phenolics in vivo. Long-term EA chow treatment (6 months) did 
not affect mouse total bone mineral density or collagen content in 
the aorta (Supplemental Figure 3, D–F), indicating that not all LOX 
family members were affected by the active compounds.
LOXL2 activity confers inhibition of TGF-β1 signaling by trihy-
droxyphenolics. To further interrogate the impact of LOXL2 inhibi-
turally identical aside from a dihydroxy- rather than the trihydroxy-
phenolic motif in EC (Supplemental Figure 1C). EC had no activity 
in our in vitro assays, whereas EGC was a potent inhibitor of Snail1 
and fibronectin in TGF-β1–stimulated A549 cells.
EA was then tested for its antifibrotic activity in vivo by either 
ad libitum feeding of chow composed of 2% wt/wt raspberry 
extract rich in EA and EA precursors given to mice or adminis-
tration of EA using osmotic pump (days 10–17) after intratracheal 
bleomycin (Figure 1D). We found that either treatment substan-
tially improved survival (Table 1) and inhibited collagen accumu-
lation (Figure 1, E and F). Because EA is poorly soluble, a more 
soluble trihydroxyphenolic-containing compound, corilagin, with 
an IC50 for EMT of approximately 50 nM (Figure 1, G and H), was 
given daily by gavage beginning 10 days after intratracheal bleo-
mycin (Figure 1I). At day 21 these mice exhibited marked attenua-
tion of bleomycin-induced total lung collagen, fibronectin, Snail1, 
and p-Smad3 (Figure 1, J and K). The average circulating level of 
corilagin 2 hours after the last dose was about 80 nM (Supple-
mental Figure 1E). EA-rich chow and corilagin had no effect on 
immune cell numbers or markers of injury (Supplemental Figure 
2). Collectively, these findings demonstrate that trihydroxypheno-
lic compounds attenuate TGF-β1–induced Snail1 and EMT markers 
in vitro as well as collagen accumulation in vivo and do so at low 
nanomolar levels. Members of this polyphenol family have previ-
ously been shown to inhibit TGF-β1 signaling at micromolar levels 
in vitro and fibrosis in vivo but by unclear mechanisms (27, 28).
To test the efficacy of EA in a second in vivo model of tissue 
fibrosis, we examined the occurrence of metastatic lung nodules 
in mice injected subcutaneously 5 weeks earlier with syngene-
ic KrasG12D/p53R172H metastatic lung cancer cells (344SQ), 
known to metastasize as a function of the cross-linked fibrillar 
collagen content of the primary tumors (Figure 2A) (29). Con-
sumption of EA-rich chow following tumor implantation mark-
edly reduced the numbers of metastatic lung nodules (Figure 2, B 
and C). Although primary tumor volume or weight was unchanged 
(Figure 2, D and E), immunohistochemistry showed significantly 
reduced collagen I expression within the primary tumors treated 
with EA chow (Figure 2F). Furthermore, immunoblotting of these 
tumor extracts also revealed attenuated total fibronectin and col-
lagen I expression, and decreased Smad activation, assessed by 
p-Smad3 (Figure 2G). Interestingly, visualizing collagen in situ 
by second-harmonics microscopy, we observed that the primary 
tumor collagen in mice fed EA chow was not only reduced but also 
exhibited more curved structures, suggesting less cross-linking 
(Figure 2, H and I, and ref. 9).
LOXL2 is identified as the target of trihydroxyphenolic-containing 
compounds. We next turned to underlying mechanisms that could 
account for the activities and potency of the polyphenolic com-
pounds. Because of the striking inhibition of Snail1 expression by 
several trihydroxyphenolic compounds (Figure 1H and Supplemental 
Figure 1B), as well as the altered collagen cross-linking structure in 
primary 344SQ tumors (Figure 2I), we explored the hypothesis that 
lysyl oxidase–like 2 (LOXL2) was their target. LOXL2 has previously 
been linked to Snail1 accumulation in tumor cells (30), and its expres-
sion is potently induced by both hypoxia and TGF-β1 (31, 32). LOXL2, 
like all mammalian copper-dependent LOX enzymes, utilizes an 
intrinsically generated quinone, termed LTQ, to mediate oxidation 
Table 1. The survival of bleomycin-treated mice by day 21 of EA 
chow and day 17 of EA pump treatment
EA Control χ2 Test
Chow
Alive 10 6
P = 0.0308
Dead 4 8
Pump
Alive 10 6
P = 0.0154
Dead 1 5
Total
Alive 20 12
P = 0.0014
Dead 5 13
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Smad activation and Snail1 induction (Figure 4F and Supplemental 
Figure 5, D–F). Together these data indicate that trihydroxypheno-
lic compounds selectively target proximal TGF-β1 signaling and 
Snail1 accumulation only in cells expressing LOXL2 and do so by a 
mechanism requiring the presence of active LOXL2.
To further investigate the specificity of trihydroxyphenolics 
for TGF-β1 signaling, we asked whether corilagin inhibited other 
kinases at 1–10 μM, well above the IC50 for its inhibitory effects 
on TGF-β1 signaling (Figure 1H). In a screen of 82 purified kinas-
es conducted at the Km  for ATP binding for each kinase, only the 
tyrosine kinases EGFR and PDGFRβ were inhibited more than 50% 
at 1 μM (Supplemental Figure 8A). However, when we specifically 
tested the inhibitory effects of corilagin at 1 μM on either EGFR or 
PDGFRβ activities of intact cells, neither were inhibited by corilagin, 
implying that the cell-free kinase screen is more sensitive than the 
inhibition of these enzymes in intact cells (Supplemental Figure 8, B 
and C). These data confirm that corilagin is not a nonspecific kinase 
inhibitor, at least at concentrations less than or equal to 1 μM.
Trihydroxyphenolics induce auto-oxidation of LOXL2 lysine 731. 
Given the structural similarities between the trihydroxyphenolic 
motif and LTQ (Figure 3A), the results described above raised the 
possibility that the trihydroxyphenolic motif operates as an LTQ-
like mimic, leading to its metabolism by LOXL2 and generating 
an inhibitor of TGF-β1 signaling. To begin testing this hypothe-
sis we inspected the LOX catalytic domain for lysines specific to 
LOXL2 and not found in LOXL1 (Figure 5A), whose silencing had 
no impact on corilagin responsiveness (Figure 3F and Figure 4D). 
tion on TGF-β1 responses, we suppressed LOXL2 levels with RNAi 
in A549 cells. Surprisingly, rather than inhibiting TGF-β1, silenc-
ing LOXL2 completely abrogated the inhibitory effects of corilagin 
on TGF-β1–induced EMT in A549 cells (Figure 3E). Further, 
LOXL2 but not LOXL1 silencing in fibroblasts completely prevent-
ed the corilagin inhibitory effects on the TGF-β1–induced mesen-
chymal proteins N-cadherin, α-smooth muscle actin, and Snail1 
(Figure 3F). These findings revealed that the corilagin mechanism 
of action was not simply LOXL2 inhibition, prompting us to revisit 
corilagin effects on TGF-β1 signaling.
Because trihydroxyphenolic compounds did not block TGF-β1–
induced p-Smad generation in short-term assays (Figure 1C), we 
considered the possibility that impaired TGF-β1 signaling was due 
to defective p-Smad nuclear import, but immunostaining revealed 
no blockade of Smad2/3 nuclear translocation within 2 hours of 
compound treatment. However, longer preincubation of cells with 
corilagin (or other trihydroxyphenolics) for several hours com-
pletely suppressed Smad activation (Figure 4A and Supplemental 
Figure 5, A–C), implying that a degree of ongoing p-Smad gener-
ation is required for regulation of the TGF-β1 gene targets studied 
here (Figure 1H). Similarly, expression of LOXL2 in NMuMG cells 
that normally express very low levels of LOXL2 conferred corilagin 
responsiveness and blockage of p-Smad3 following 6-hour pre-
treatment (Figure 4B). Conversely, silencing LOXL2 in A549 cells 
and primary lung fibroblasts completely blocked corilagin effects 
on p-Smad3 generation (Figure 4, C and D). Consistent with a 
critical role for LOXL2 in proximal TGF-β1 signaling, a survey of 
numerous cell lines revealed a direct correlation of LOXL2 mRNA 
levels with the degree of inhibition of TGF-β1–induced Smad acti-
vation by corilagin (Supplemental Figure 6). To further test this 
principle in vivo, epithelial, fibroblast-rich mesenchymal, and 
immune cells were isolated by flow cytometry from pools of normal 
lungs and lungs of mice exposed 14 days earlier to bleomycin, then 
immediately stimulated with TGF-β1 and tested for their degree 
of p-Smad accumulation as a marker of TGF-β1 signaling (Figure 
4E). There was a marked attenuation of p-Smad3 in the fibro-
blast-rich lung fraction of bleomycin-exposed mice also given oral 
epigallocatechin-3-gallate (EGCG; 100 mg/kg daily) but no dis-
cernible inhibition of p-Smad3 in either the epithelial or immune 
cell fractions. A second experimental design in which the isolated 
fractions from pools of normal lungs and lungs of mice exposed 
14 days earlier to bleomycin fed with control or EA chow demon-
strated the same pattern (Supplemental Figure 7), confirming the 
cell selectivity of trihydroxyphenolics on TGF-β1 signaling in vivo. 
Finally, we confirmed that inhibition of active LOXL2 by the copper 
chelator d-penicillamine (DPA) also abrogated corilagin effects on 
Figure 2. EA-rich diet attenuates 344SQ lung tumor metastasis and primary tumor collagen cross-linking. (A) Implantation and treatment in syngeneic lung 
cancer model. Metastatic 344SQ tumor cells were subcutaneously injected in syngeneic mice at 12 weeks old and treated with ctl or EA chow for 5 weeks. (B) 
Representative pictures of lung metastasis of 344SQ tumors treated with ctl or EA chow. (C) Quantification of lung metastasis of 344SQ tumors treated with ctl 
or EA chow (n = 14 mice per group). (D) Total volume of 344SQ tumors treated with ctl or EA chow (n = 14 mice per group). (E) Total tumor weight (grams) of ctl 
or EA chow–treated 344SQ primary tumors (n = 14 mice per group). (F) Collagen I immunohistochemistry (IHC) of 344SQ primary tumors treated with ctl or EA 
chow. Scale bars: 50 μm. (G) Ctl or EA chow–treated 344SQ primary tumors were lysed and immunoblotted for fibronectin, collagen I, β-actin, p-Smad3, and total 
Smad3. Quantification of bands normalized to β-actin was pooled from 10 mice per group. Data represent mean ± SD. Each protein was analyzed by 1-way ANOVA 
with a Tukey post hoc test. (H) Representative second-harmonic generation (SHG) images from 344SQ primary tumors treated with ctl or EA chow. Scale bars: 50 
μm. (I) Quantification of curvature ratio for individual collagen fibers imaged by SHG microscopy of primary 344SQ tumor tissues treated with ctl (n = 102  
collagen fibers per sample) or EA chow (n = 141 collagen fibers per sample). Data for C–E and I are expressed as mean ± SD. P value by unpaired 2-tailed t test.
Table 2. Collagen cross-links in 344SQ tumors treated with ctl or 
EA chow (moles per mole of collagen)
Ctl chow,  
mean (±SD) (n = 3)
EA chow,  
mean (±SD) (n = 3)
Ctl vs. EA,  
P value
DHLNL 0.1 (0.00) 0.05 (0.01) 0.005
HLNL 0.39 (0.02) 0.25 (0.02) 0.0015
HHMD 0.23 (0.07) 0.14 (0.06) 0.26
PYD 0.19 (0.00) 0.26 (0.07) 0.33
DPD 0.039 (0.01) 0.022 (0.01) 0.0221
LOXL2 mediates the conversion of Lys to Lysald, which is ultimately processed 
to HHMD. LOXL2 also mediates the conversion of Hyl to Hysald. Hylald can then 
be converted into DHLNL and subsequently PYD, Hylald can be converted to 
HLNL and subsequently DPD. DHLNL, dehydro-dihydroxylysinonorleucine/ 
its ketoamine; HLNL, dehydro-hydroxylysinonorleucine/its ketoamine; 
HHMD, dehydro-histidinohydroxymerodesmosine; Lys, lysine; Hyl, 
hydroxylysine; ald, aldehyde.
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We then established and expressed Flag-tagged point mutants of 
each of 3 LOXL2/3–specific lysines, converting each to the corre-
sponding LOXL1 residues: K614N, K731R, and K759R. Each of 
the point mutants had comparable enzyme activity to WT LOXL2 
when expressed in NMuMG cells (Supplemental Figure 9A), and 
all except the K731 mutant were completely inhibited by corilagin 
(Figure 5B). Cells expressing K731R LOXL2 were completely 
resistant to inhibition of TGF-β1 signaling (Figure 5C) and Snail1 
stabilization (Figure 5D) by corilagin, whereas the other mutants 
were indistinguishable from WT. Because lysine auto-oxidation 
by LOX family enzymes is critical to LTQ generation, we asked 
whether K731 was auto-oxidized to an aldehyde in the presence of 
corilagin. Incubation of a biotin hydrazide that covalently links to 
free aldehydes with immunoprecipitated WT and mutant LOXL2 
confirmed that each enzyme except the K731R mutant developed 
an aldehyde when mixed with corilagin, implying that K731 but 
not other lysines is converted to an aldehyde during metabolism 
of corilagin by LOXL2 (Figure 5E).
A novel TβRI kinase inhibitor is generated inside LOXL2-expressing 
cells. We next screened compounds structurally similar to the inter-
mediate aminophenol known to appear during the LTQ cycle (Fig-
ure 3A) for direct TGF-β1 inhibition. A catechol containing an amino 
group at position 3 (3Abd, 3-aminobenzene-1,2-diol) but not at either 
position 2 (2Abd) or 4 (4Abd) was found to be a potent inhibitor of 
TGF-β1–induced Smad3 activation and Snail1 expression without 
preincubation and regardless of LOXL2 expression (Figure 6, A–C, 
and Supplemental Figure 9B). We confirmed that 3Abd, but not con-
trol pyrogallol or 2Abd, directly blocked the kinase activity of recom-
binant TβRI catalytic domain with an IC50 of approximately 3 μM 
(Figure 6D and Supplemental Figure 9C), consistent with the inhibi-
Figure 3. Identification of LOXL2 as the target of EA and corilagin; requirement for active LOXL2 for corilagin-induced inhibition of EMT and Snail 
expression. (A) LTQ cycle. LTQ converts lysine to allysine and yields an aminophenol intermediate. Subsequent hydrolysis release allysine and the 
original cofactor, producing hydrogen peroxide and ammonia as side products. (B) Primary human lung fibroblasts cultured in the presence of vitamin C 
and dextran sulfate were treated with recombinant human LOXL2 and different inhibitors for 7 days. The insoluble cross-linked collagen was extracted 
and measured by Sircol assay. SB, SB431542, TβRI inhibitor; NAC, N-acetylcysteine, antioxidant. STD, standard. (C) Recombinant human LOXL2 was 
incubated with 2 mM d-penicillamine (DPA) or different concentrations of corilagin (0–1 μM) for 1 hour, and LOX activity was measured. Data represent 
mean ± SD; n = 3. (D) NMuMG cells overexpressing human LOXL2 were incubated with or without 0.5 μM corilagin for 24 hours, lysed, and immunoblot-
ted for LOXL2, Snail1, and β-actin. (E) A549 cells transfected with siRNA to LOXL2 were stimulated with TGF-β1 or left unstimulated for 48 hours in the 
presence or absence of 1 μM corilagin. The lysates were immunoblotted for LOXL2, fibronectin, E-cadherin, Snail1, and β-actin. (F) Primary human lung 
fibroblasts transfected with siRNAs to LOXL1 or LOXL2 were stimulated with TGF-β1 or left unstimulated for 72 hours in the presence or absence of 1 
μM corilagin, and the lysates were immunoblotted for LOXL1, LOXL2, N-cadherin, α-smooth muscle actin (α-SMA), Snail1, and β-actin. B and D–F are 
representative of at least 3 experiments with similar results.
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tory profile of 3Abd in cells (Figure 6C). In cells overexpressing TβRI 
we also observed that 3Abd but not control 3Fc (3-Fluorocatechol) 
blocked the kinase activity of immunoprecipitated TGF-β receptors 
(Supplemental Figure 9D). Notably, 3Abd is structurally distinct 
from any of the known low–molecular weight inhibitors of TβRI (18).
To further define the mechanism of TGF-β1 inhibition by tri-
hydroxyphenolic compounds, we asked whether secreted LOXL2 
generated active 3Abd-like metabolites. Overnight coculture 
of corilagin-treated A549 cells with corilagin-nonresponsive 
NMuMG cells (Figure 4B) expressing a Smad3 reporter (12X 
CAGA) (40) revealed indistinguishable TGF-β1–induced reporter 
activation with or without 5-fold excess A549 cells in coculture, 
indicating that the generation of a diffusible inhibitor was unlikely 
(Figure 6E). In addition, lysates of corilagin-treated A549 cells, 
but not that of untreated cells, inhibited the kinase activity of 
immunoprecipitated TGF-β receptors (Figure 6F). These results 
point to an intracellular origin of a trihydroxyphenolic metabo-
lite(s) inhibiting TβRI kinase (Figure 6G). While we demonstrated 
that the small fragment 3Abd that would result from a trihydroxy-
phenolic acting through an LTQ-like mechanism (and not pyrogal-
lol) directly inhibits TβRI kinase (Figure 6D), future studies will be 
needed to isolate the exact inhibitory metabolite(s) present within 
trihydroxyphenol-treated LOXL2-expressing cells.
Discussion
These studies reveal, for the first time to our knowledge, a pathway 
of inhibition of the TGF-β1–induced collagen program selective to 
the cells that are most accountable for pathological collagen depo-
Figure 4. Corilagin inhibition of TGF-β1 signaling is dependent on LOXL2 activity. (A) A549 cells pretreated with 1 μM corilagin for 0, 3, or 6 hours were stim-
ulated with different doses of TGF-β1 (0, 0.2, or 1 ng/ml) for 30 minutes, and the cell lysates were blotted for p-Smad2, p-Smad3, Smad2, Smad3, and β-actin. 
(B) NMuMG cells transfected with human LOXL2 or empty vector were pretreated with 1 μM corilagin or DMSO for 6 hours and then incubated without or with 
TGF-β1 for 30 minutes. The cell lysates were blotted for LOXL2, p-Smad3, Smad3, and β-actin. (C and D) A549 cells transfected with siRNA to LOXL2 (C) and 
primary human lung fibroblasts transfected with siRNAs to LOXL1 or LOXL2 (D) were pretreated with 1 μM corilagin or DMSO for 6 hours before incubation 
without or with TGF-β1 for 30 minutes. The cell lysates were blotted for p-Smad3 and Smad3. The ratio of p-Smad3/Smad3 for each lane is shown. (E) Mouse 
lung epithelial cells, fibroblasts, and immune cells sorted from mice treated for 14 days with saline (S), bleomycin with vehicle control (BC), or bleomycin with 7 
days oral EGCG (100 mg/kg) (BE) were immediately treated with TGF-β1 for 30 minutes and cell lysates blotted for p-Smad3, total Smad3, and β-actin.  
n = 5 for each group. (F) A549 cells were pretreated with 1 μM corilagin with or without 2 mM DPA for 6 hours before TGF-β1 stimulation for 30 minutes. The 
cell lysates were blotted for p-Smad3, Smad3, and β-actin. The data from A–D and F are representative of at least 3 experiments with similar results.
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that of previously described extracellular LOXL2 inhibitors as 
well as global LOX inhibitors, accounting for the lack of negative 
impact of long-term exposure to EA-rich compounds on bone or 
vascular collagen content (Supplemental Figure 3, D–F, and refs. 
34, 41). Maintenance of musculoskeletal and vessel wall collagen 
and elastin integrity depends on LOX and LOXL1, not LOXL2 
(42–45). Although selective, the combined inhibition of LOXL2 
and TGF-β1 signaling in fibroblast-like cells results in potent in 
vivo antifibrotic activity that has untapped but promising potential 
as a therapeutic approach for chronic diseases such as pulmonary 
fibrosis dominated by progressive collagen accumulation.
The combined inhibition of LOXL2 and TGF-β1 signaling in 
fibroblast-like cells could be expected to impact biomarkers of col-
lagen turnover in vivo. Indeed, we observed an increase in urinary 
levels of pyridinoline (PYD) and DPD, nonreducible end products 
of cross-linked collagen metabolism, in mice 10–21 days after 
sition, tissue fibroblasts and fibroblast-like tumor cells. The sur-
prising finding that such selectivity depends on active LOXL2/3 
and appears to operate in a cell-autonomous manner largely abro-
gates inhibition by trihydroxyphenolic-containing compounds of 
TGF-β1 signaling in epithelial or immune cells that don’t express 
LOXL2/3. This selectivity likely avoids the toxicities of long term 
general TGF-β1 inhibition in chronic disease processes such as 
fibrosis and cancer progression. Indeed, we have observed no 
adverse events in mice on the trihydroxyphenolic-rich diet (EA 
chow) for at least 6 months, including the absence of skin inflam-
mation and discernible lesions in cardiac valves. Likewise, none of 
the compounds tested here had any negative effects on cell viabil-
ity in vitro at concentrations up to 10 μM of trihydroxyphenolics or 
50 μM of 3Abd (Supplemental Figure 10). The selective inhibition 
of intracellular and extracellular LOXL2/3 by trihydroxyphenolics 
also distinguishes this mechanism of LOX family inhibition from 
Figure 5. Trihydroxyphenolic motif mimics the LTQ, leading to auto-oxidation of LOXL2 K731 and inactivation of LOXL2. (A) Catalytic domain sequence 
of LOXL2. Catalytic domain: P548–S751. LTQ sites are highlighted and boldface (K653 and Y689). The 3 point mutation sites are in red (K614N, K731R, 
K759R). (B) NMuMG cells transfected with WT or mutant human LOXL2 were treated with 1 μM corilagin or DMSO for 6 hours. LOX activity of conditioned 
media from treated cells was measured. Data are presented as percent activity of no-corilagin control. Mean ± SD, n = 3. (C) NMuMG cells transfected with 
WT or mutant human LOXL2 were pretreated with 1 μM corilagin or DMSO for 6 hours and then incubated without or with TGF-β1 for 30 minutes. The cell 
lysates were immunoblotted for LOXL2, p-Smad3, Smad3, and β-actin. (D) NMuMG cells transfected with WT or mutant human LOXL2 were incubated 
with or without 1 μM corilagin for 24 hours, and lysates were immunoblotted for LOXL2, Snail1, and β-actin. (E) NMuMG cells transfected with WT or 
mutant human LOXL2 were incubated with 1 μM corilagin for 6 hours and labeled with 2.5 mM biotin hydrazide for 2 hours. The biotin hydrazide–linked 
carbonylated LOXL2 was pulled down with streptavidin–magnetic beads, and the precipitates and input protein were immunoblotted for LOXL2. C–E are 
representative of at least 3 experiments with similar results.
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Figure 6. Generation of a novel nondiffusible TβRI kinase 
inhibitor. (A) Structure of pyrogallol (Pg), 3Abd, and deriv-
atives. (B) A549 cells were stimulated with TGF-β1 for 30 
minutes and lysates immunoblotted for p-Smad3, Smad3, and 
β-actin. Treatment without preincubation: 3Abd (0.5–10 μM); 
2Abd or 4Abd (1, 10 μM). (C) A549 cells were stimulated with 
TGF-β1 for 48 hours and lysates immunoblotted for LOXL2, 
fibronectin, E-cadherin, Snail1, and β-actin. 3Abd was added 
at concentraions ranging from 0.5 to 10 μM. (D) Purified ALK5/
TβRI catalytic domain kinase assay was performed with 10 
doses of 3Abd or Pg starting from 100 μM. Kinase activity was 
indicated by 33P-ATP signals, and IC50 of 3Abd was calculated as 
approximately 3 μM. B–D are representative of 3 experiments 
with similar results. (E) SMAD-binding element (SBE) reporter–
transfected NMuMG and A549 cells were seeded into a 96-well 
plate. Cocultured wells were seeded with 5,000 transfected 
NMuMG cells and 25,000 nontransfected A549 cells. Cells 
were pretreated with or without 1 μM corilagin, 1 μM EGCG, 10 
μM 3Abd, or 5 μM SB431542 for 6 hours and stimulated with 
TGF-β1 overnight before lysis for luciferase assay. Data are 
presented as percent TGF-β1–induced SBE luciferase activity 
of DMSO control in log scale. Mean ± SD, n = 3. (F) Flag-tagged 
TβRI and TβRII were immunoprecipitated from A549 cells and 
in vitro kinase assay performed on beads exposed to lysate 
pretreated with corilagin or DMSO. The final reaction was  
eluted and analyzed by immunoblotting for phosphotyrosine 
and TβRI. The phosphotyrosine bands were quantified using 
ImageJ and normalized to DMSO control. Data represent  
mean ± SD. P value by unpaired 2-tailed t test of 6 separate 
experiments. (G) Schematic overview of mechanism. A  
trihydroxyphenolic-containing compound engages active 
LOXL2, initiating auto-oxidation of K731 and creating a key 
allysine inactivating the enzyme. In the process, a 3Abd-like 
metabolite is generated that then blocks TβRI kinase. The 
combined effects block pathological collagen accumulation. 
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(100-21) was from PeproTech. 3-Aminobenzene-1,2-diol (3Abd; 
W4593) was from Aurum Pharmatech Inc. 2-Aminobenzene-1,3-di-
ol (2Abd; 23488), 4-aminobenzene-1,2-diol (4Abd; 31975), and 3- 
fluorocatechol (CL8492) were from AstaTech Inc. Human recombi-
nant LOXL2 (2639-AO-010) was purchased from R&D Systems.
Cell culture. Human or mouse cell lines were purchased from 
ATCC and grown in DMEM or RPMI 1640 medium supplemented 
with l-glutamine and 10% FBS (Hyclone). Human and mouse lung 
fibroblasts were isolated from crude whole-lung single-cell suspen-
sion cultures on Petri dish in DMEM supplemented with l-glutamine 
and 10% FBS for 2 weeks. Mouse type II alveolar epithelial cell isola-
tion and culture were performed as previously described (57). All the 
cell lines in the laboratory are periodically tested for mycoplasma con-
tamination. Only the mycoplasma-free cells are used for experiments.
High-throughput screen and high-content imaging analysis. A549 
cell–based screening for inhibitors of TGF-β1–induced EMT from 
small-molecule libraries was performed in 384-well plate format, and 
the images were captured and analyzed using GE IN Cell 2000 as 
described previously (26).
Immunofluorescence. Cultured cells and 5- to 7-μm cryosections 
were fixed in 4% paraformaldehyde and stained with various antibod-
ies and IgG isotype controls. Where indicated in the figure legends, 
mosaic images were generated from multiple ×20 images captured 
on a Zeiss Axio upright fluorescent microscope and tiled using 10% 
image overlap by Axiovision 4.7 software (Zeiss).
Masson’s trichrome stain. For histological assessment of lung collagen, 
frozen sections of the left lung were stained using Masson’s trichrome 
stain kit (22-110-648, Thermo Fisher Scientific). The whole section was 
imaged with a Zeiss Axio upright microscope and tiled using 10% image 
overlap into a single panoramic by Axiovision 4.7 software (Zeiss).
Immunoblot. Pulverized tissue and cells were lysed in RIPA buffer 
(150 mM NaCl, 50 mM Tris, pH 8.0, 1% Triton X-100, 0.5% sodium 
deoxycholate, 0.1% SDS, supplemented with protease and phospha-
tase inhibitors) and analyzed by immunoblotting. Densitometry was 
quantified using NIH ImageJ software. See complete unedited blots in 
the supplemental material.
Bleomycin fibrosis model. Eight-week-old C57BL/6 mice were intratra-
cheally instilled with saline or 1.9 units/kg of bleomycin (Sigma-Aldrich). 
Mice were implanted with Alzet osmotic pumps (1007D, DURECT Corp.) 
loaded with EA salt (24 mg/kg/d, days 10–17), fed with red raspberry diet 
(EA chow, days 0–21), or gavaged with corilagin (100 mg/kg, days 10–21). 
Controls were treated with control pump, control diet, or vehicle in the 
same formulation. Red raspberry diet (TD.130761) and red control diet 
(TD.150279) was custom-made by Envigo. The lungs were lavaged, and 
then embedded in OCT compound for imaging or snap-frozen in liquid 
nitrogen for protein extraction or hydroxyproline assay.
Syngeneic in vivo tumorigenesis and metastasis assays. KrasG12D/
p53R172H metastatic lung cancer cells (344SQ) were subcutaneously 
injected in the right flanks of male, syngeneic 129/Sv mice at 3 months 
of age and allowed to form tumors for 5–6 weeks (29). The mice were 
fed with red raspberry diet or control diet. After euthanasia, tumors 
were measured and lung metastatic nodules were quantified. Pri-
mary tumor tissues were snap-frozen and analyzed by Western blot. 
Some primary tumors were formalin fixed, paraffin embedded, and 
sectioned for immunohistochemistry or second-harmonic generation 
imaging. The investigators were completely blinded to drug treat-
ment and outcome assessment.
bleomycin injection, and this increase was suppressed by treat-
ment of the mice with corilagin (Supplemental Figure 11A). Con-
sistent with these findings, we observed increased mean urinary 
PYD/DPD levels in 2 cohorts of patients with idiopathic pulmo-
nary fibrosis (Supplemental Figure 11B), suggesting that a signal 
from fibrotic lungs is present in most of these patients and may 
enable tracking of collagen turnover and drug responses in vivo.
The biological pathway identified here uses trihydroxy- 
containing polyphenols at concentrations achievable by dietary 
ingestion. Indeed, foods rich in this class of compounds, such as 
EGCG (the major polyphenol in green tea), have been consumed 
as therapeutics for decades (46). Yet these compounds are not 
generally thought of as workable drugs because of their potential 
for pro- and antioxidant reactions that could negatively impact 
pathways, such as drug metabolism, sensitive to such reactions 
(47). The designation of these polyphenols as antioxidants and 
as reactive compounds, however, largely stems from prior stud-
ies that have used micromolar levels of polyphenols to achieve 
in vitro “antioxidant” or signaling inhibition in multiple cell sys-
tems (48), even though blood levels above approximately 150 nM 
have not been documented for dietary polyphenols consumed by 
humans (49–53). As well, we observed no neutralization of H2O2 
oxidant activity by corilagin at concentrations below 10 μM (Sup-
plemental Figure 4). We believe the LOXL2-dependent interac-
tion with trihydroxyphenolics is a singular example of a relevant 
protective pathway activated by nanomolar levels of the relevant 
ellagitannin and catechin subclasses, possibly contributing to the 
observed beneficial effects of green tea and other trihydroxyphe-
nolic-rich diets in numerous population studies (54–56).
Methods
Reagents. Ellagic acid (EA; E2250), epigallocatechin gallate (EGCG; 
E4143), epicatechin gallate (E3893), epigallocatechin (EGC; E3768), 
gallocatechin (E3768), epicatechin (EC; E1753), catechin (C1251), lute-
olin (L9283), chloramine T (857319), p-dimethylaminobenzaldehyde 
(156477), bleomycin (B5507), d-penicillamine (DPA; P4875), pyro-
gallol (254002), N-acetylcysteine (A7250), protease inhibitor cocktail 
(P8340), phosphatase inhibitor cocktail (P5726), fibronectin polyclonal 
antibody (pAb) (F3648), α-smooth muscle actin mAb (A5228), Flag 
M2 mAb (F3165), and β-actin mAb (A5441) were purchased from 
Sigma-Aldrich. Corilagin (23094-69-1) was purchased from BOC 
Sciences. TGF-β type I receptor inhibitor SB431542 (S4317), phos-
pho-Smad2 (Ser465/467) pAb (566415), EGFR pAb (06-847), and 
phosphotyrosine mAb 4G10 (05-321) were from EMD Millipore. Snail1 
mAb (3895), Smad2 mAb (5339), phospho-Smad1/5 (Ser463/465) pAb 
(9516), Smad1 pAb (9743), phospho-EGFR pAb (2231), phospho-PDG-
FRβ pAb (3161), and PDGFRβ Rb mAb (3169) were from Cell Signal-
ing Technology. Collagen I pAb (ab292), vimentin mAb (ab45939), 
LOXL2 pAb (ab96233) for Western blot, and phospho-Smad3 
(Ser423/425) pAb (ab52903) were from Abcam. SiRNAs for human 
LOXL1 (sc-45220) and LOXL2 (sc-45222) and secondary HRP- 
conjugated antibodies (mouse, sc-2005; rabbit, sc-2004) were from 
Santa Cruz Biotechnology. Streptavidin–magnetic beads (11205D), 
TurboFect transfection reagent (R0531), and EZ-Link Hydrazide- 
LC-Biotin (PI21340) were from Thermo Fisher Scientific. Protein G–
agarose (11719416001) was from Roche. E-cadherin (610182) and 
N-cadherin (610921) antibodies were from BD Biosciences. TGF-β1 
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cence plate reader (BMG LabTech FLUOstar) at excitation (Ex)/emis-
sion (Em) = 540/590 nm. Sample buffer or medium alone without 
LOXL2 was used for determination of the background fluorescence.
Collagen cross-link analysis. Snap-frozen primary 344SQ tumors 
were pulverized in liquid nitrogen using a Spex Freezer Mill (Spex), 
washed with cold PBS and cold distilled water, lyophilized, and 
weighed. Aliquots were reduced with standardized NaB3H4 and hydro-
lyzed with 6N HCl. The hydrolysates were then subjected to amino 
acid and cross-linking analyses using liquid chromatography–tandem 
mass spectrometry (LC–MS/MS) as described previously (59). The 
terms DHLNL, HLNL, and HHMD represent both the unreduced and 
reduced forms. The mature trivalent cross-links, PYD and DPD, were 
simultaneously analyzed by their fluorescence. All cross-links were 
quantified as the moles per mole collagen based on the value of 300 
residues of hydroxyproline per collagen molecule.
Urinary PYD/DPD measurements. Pooled urine from each of 3–5 
mice for each time point after bleomycin in a cohort of mice treated with 
vehicle or corilagin (100 mg/kg) beginning on day 10 after bleomycin 
was collected. Urine specimens were also collected from 2 cohorts of 
idiopathic pulmonary fibrosis patients and controls at 2 sites: The Uni-
versity of Texas Health Science Center at San Antonio and UCSF. All 
consenting patients with physician-established diagnosis of idiopathic 
pulmonary fibrosis followed in the respective interstitial lung disease 
(ILD) programs were included in sample collection. PYD/DPD levels 
from all the samples were measured using MicroVue EIA Assay Kit 
(catalog 8010) and MicroVue Creatinine EIA Kit (catalog 8009, Quidel 
Corp.) along with PYD/DPD standards, and the results were normal-
ized relative to urinary creatinine. The statistical significance of human 
urine samples was analyzed using Mann-Whitney U test.
Bone mineral density measurement. Bone mineral density of mice 
treated with red raspberry diet or control diet up to 6 months was mea-
sured using dual-energy X-ray absorptiometry (DEXA) scan. DEXA 
scans were performed using the Lunar PIXImus Densitometer (GE 
Medical Systems) at the UCSF animal facility. The PIXImus Densitom-
eter was calibrated before each testing using a quality control phantom 
following the manufacturer’s instructions.
Elastic Van Gieson stain. Aortas isolated from mice treated with 
red raspberry diet or control diet up to 6 months were embedded in 
paraffin (n = 3 per group). Sections (5 μm) were cut every 30 μm along 
the aortas (starting from the proximal end). Selected sections were 
stained with Miller’s Elastica Van Gieson stain.
Site-directed mutagenesis of LOXL2. Site-directed mutagenesis was 
performed to generate K614N, K731R, and K759R point mutations 
using Phusion Site-Directed Mutagenesis Kit (F541, Thermo Fisher 
Scientific) according to the manufacturer’s instructions. A pcDNA3-
hLOXL2-Flag plasmid containing the cDNA fragment of WT human 
LOXL2 fused with a Flag tag at the C-terminus (gift from Amparo Cano, 
Instituto de Investigaciones Biomédicas, Universidad Autónoma de 
Madrid/Consejo Superior de Investigaciones Científicas, Madrid, 
Spain) (30) was used as the template DNA (30). Mutations were con-
firmed by DNA sequencing. The primers and their complementary 
strands used were: K614N forward 5′-GACTTCCGGCCTAATA-
ATGGCCGC-3′, K614N reverse 5′-GGACTGGCCATTGTTGTG-
GATCTG-3′; K731R forward 5′-ACAACATCATACGATGCAGGAG-
CC-3′, K731R reverse 5′-TGGAGTAATCGGATTCTGCAACCT-3′; 
K759R forward 5′-ACGGAAAAACGTTTTGAGCACTTCA-3′, and 
K759R reverse 5′-CTCTTCGCTGAAGGAACCACCTAT-3′.
Immunohistochemistry and second-harmonic generation micros-
copy. Paraffin-embedded tissue sections were rehydrated, blocked 
with goat serum, and probed for collagen I. Tissues were subse-
quently washed and probed with HRP-conjugated secondary anti-
bodies, and signal was attained by developing with a DAB reagent. 
Collagen cross-linking alteration was evaluated by second-harmon-
ic generation microscopy. Tissues stained by H&E were visualized 
using a Zeiss LSM 7 MP Multiphoton Microscope at an excitation 
wavelength of 800 nm, and collagen fiber signals were detected at 
380–430 nm using bandpass filters. Collagen linearity was calculat-
ed as a ratio of the total length versus the end-to-end length of the 
individual collagen fiber.
Collagen content. Lung or aorta collagen content was evaluat-
ed using hydroxyproline assay (58). Briefly, whole left lung tissue 
or aorta was hydrolyzed in 1 ml 12N HCl at 110°C for 24 hours, the 
hydroxyproline was detected by incubation with chloramine T and 
p-dimethylaminobenzaldehyde, and the absorbance was measured 
at 550 nm. Each sample was run in triplicate. Collagen content in 
lung or aorta tissues was expressed as micrograms of collagen per 
lung or aorta and was converted from micrograms of hydroxyproline.
Bronchoalveolar lavage. After the trachea was exposed, a 20-gauge 
catheter was inserted into the trachea through a small incision. One 
milliliter cold PBS was instilled into the mouse lungs followed by gentle 
aspiration, and this was repeated 2 more times. All the bronchoalveolar 
lavage fluid (BALF) was centrifuged, and the cell pellet was resuspended 
in erythrocyte (rbc) lysis buffer (Sigma-Aldrich) followed by recentrif-
ugation. Cell number was counted using a hemocytometer. Cell types 
of BALF were determined by morphology following Diff-Quik stain of 
cytospin slides. About 500 cells were counted for each sample in order to 
determine the cell types. Macrophages account for more than 80% of the 
cells in BALF and were collected by centrifugation. After centrifugation, 
the supernatant was collected to measure total protein content using the 
BCA assay (23225, Pierce), while the cell pellet was lysed for immunoblot-
ting or RNA isolation.
Plasma level of corilagin. Plasma level of corilagin in C57BL/6 mice 
2 hours following the last oral administration at day 21 was analyzed 
by Quintara Discovery. Blood samples (~500 μl/sample) were collected 
via cardiac puncture. Samples were placed in tubes containing heparin 
sodium and stored on ice until centrifuged for plasma.
Preparation of insoluble cross-linked collagen. Fibroblasts were cul-
tured on a 10-cm dish until confluent. The medium was then changed 
to DMEM containing 5% FBS, 100 μM l-ascorbic acid with 500 kDa 
dextran sulfate at 100 μg/ml, and 50 ng/ml recombinant human 
LOXL2 for 7 days (36, 37). The cell layer was extracted with 0.5 M ace-
tic acid and 0.1 mg/ml pepsin overnight at 4°C. The leftover insoluble 
fraction was further extracted and the insoluble cross-linked collagen 
measured using Sircol Insoluble Collagen Assay kit (S1000, Biocolor) 
according to the manufacturer’s instruction.
LOX activity assay. LOX activity of recombinant human LOXL2 or 
conditioned medium collected from cells expressing LOXL2 was mea-
sured using a Fluorometric Lysyl Oxidase Activity Assay Kit (ab112139, 
Abcam) following a protocol provided by the manufacturer. Briefly, 50 
μl of sample was mixed with an equal volume of assay reaction mixture 
containing LOX substrate, HRP, and HRP substrate in the presence 
and absence of testing inhibitors and d-penicillamine (DPA), a LOX 
inhibitor. The mixture was incubated for 30 minutes at 37°C in dark-
ness. The fluorescence increase was then measured with a fluores-
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incubated for 1 hour at 4°C with the following primary antibodies: rat 
anti–mouse CD45–APC-Cy7 (1:100; BD, 557659), rat anti–mouse 
PeCAM–PE (1:100; BD, 553373), rat anti–mouse EpCAM–Alexa Fluor 
488 (1:250; BioLegend, 118210), and viability dye Sytox blue (1:1,000; 
Thermo Fisher Scientific, S34857). Cell sorting was performed on 
BD FACS Aria cytometers. EpCAM+ and CD45+ cells were collected, 
respectively. EpCAM/CD45/CD31–triple-negative cells were collected 
as mesenchymal cells. Each of the 3 cell types sorted from saline con-
trol, bleomycin control, and bleomycin EGCG groups (n = 5) were lysed 
and blotted for p-Smad3 and total Smad3.
Protein and lipid kinase screen. Protein kinase assays were conducted 
using the KinaseProfiler service of Eurofins Pharma Discovery Services 
UK Ltd. The kinase of interest was incubated with the test compound 
in assay buffer containing substrate, 10 mM magnesium acetate, and 
[γ-33P-ATP]. The reaction was initiated by the addition of the Mg/ATP 
mix. After incubation at room temperature, the reaction was stopped by 
the addition of a 3% phosphoric acid solution. An aliquot of the reaction 
was then spotted onto a filtermat and washed in phosphoric acid fol-
lowed by a rinse in methanol prior to drying and scintillation counting. 
Results were expressed in relation to controls containing DMSO only 
in place of test compound. The ATP concentration in each assay was 
within 15 μM of the determined apparent Km for ATP.
Lipid kinase assays were conducted using the KinaseProfiler ser-
vice of Eurofins Pharma Discovery Services UK Ltd. The kinase of 
interest was incubated in assay buffer containing substrate and Mg/
ATP. The reaction was initiated by the addition of the Mg/ATP solu-
tion. After incubation for 30 minutes at room temperature, the reac-
tion was stopped by the addition of stop solution containing EDTA 
and a biotinylated form of the reaction product. Finally, detection 
buffer was added, containing europium-labeled anti-GST monoclo-
nal antibody, a GST-tagged lipid binding domain, and streptavidin- 
conjugated allophycocyanin. The plate was then read in time-resolved 
fluorescence mode, and the homogeneous time-resolved fluores-
cence (HTRF) signal was determined according to the formula HTRF 
= 10,000 × (Em665nm/Em620nm).
H2O2 scavenging assay. The oxidant scavenging activity of corilagin 
and vitamin C was measured using Amplex Red Hydrogen Peroxide/
Peroxidase assay kit (Thermo Fisher Scientific, A22188) following the 
manufacturer’s instructions. H2O2 (0.5 μM) samples were incubated 
with different concentrations of corilagin (0–100 μM) and vitamin C 
(0–10 μM) for 2 hours at room temperature before Amplex Red/HRP 
reaction and the plate read at Ex/Em 540/590 nm with a fluorescence 
plate reader (BMG LabTech FLUOstar). Compound vehicle was used 
for determination of the background fluorescence. Experiments were 
performed in triplicate, and data are presented as means ± SD.
Cell viability assay. AlamarBlue cell viability reagent (Thermo 
Fisher Scientific, DAL1025) was used to assess cell viability. A549 
or human primary lung fibroblasts (20,000 cells) in complete RPMI 
or DMEM medium were seeded into a 96-well tissue culture plate 
overnight; then the cells were exposed to different compounds for 72 
hours. AlamarBlue reagent (1:10) was added to the cells, followed by 2 
hours of incubation at 37°C, and absorbance at 570 nm was measured. 
Experiments were performed in triplicate using different batches of 
cells, and data are presented as means ± SD.
Statistics. Descriptive statistics are reported as means ± SD. For 
evaluation of differences between compound treated and control 
groups, the unpaired 2-tailed Student’s t test or Mann-Whitney U 
Biotin hydrazide derivatization of carbonylated LOXL2. NMuMG 
cells were transiently transfected with WT or mutant human LOXL2-
Flag in a 10-cm dish, and 24 hours later the cells were treated with 1 
μM corilagin for 6 hours at 37°C before lysis in 50 mM HEPES, 100 
mM NaCl, 2 mM EDTA, 0.5% Triton-100 plus protease inhibitor 
cocktail, 10 mM NaF, 1 mM Na3VO4. The lysates were incubated with 
2.5 mM EZ-Link Hydrazide-LC-Biotin in the dark for 2 hours at room 
temperature. Biotin hydrazide–bound proteins were captured using 
streptavidin–magnetic beads (Pierce) on a rotary mixer at 4°C over-
night. The beads were washed 3 times with lysis buffer and eluted with 
sample buffer for 10 minutes at 70°C. Biotin hydrazide–linked carbo-
nylated LOXL2 and total input LOXL2 were detected by LOXL2 poly-
clonal antibody or Flag monoclonal antibody (M2) blot.
In vitro TGF-β receptor kinase assay. A549 cells were transiently 
cotransfected with Flag-tagged human TGF-β receptor I and II. After 
24 hours the cells were lysed in 1% NP-40 lysis buffer (1% NP-40, 20 
mM Tris, pH 7.6, 200 mM NaCl plus protease inhibitor cocktail, 10 mM 
NaF, 1 mM Na3VO4), and the type I and II receptors were immunopre-
cipitated using anti-Flag antibody and Protein G–Agarose (Roche). The 
beads were washed 3 times with kinase buffer (0.01% Triton X-100, 25 
mM HEPES, pH 7.4, 2 mM MnCl2, 10 mM MgCl2, 20 μM DTT, 0.1 mM 
NaF, 0.1 mM Na3VO4). The kinase reactions were initiated by addition 
of 0.1 mM ATP in the presence or absence of inhibitors or lysate from 
A549 cells pretreated with corilagin (1:10 dilution into kinase reaction). 
The kinase reactions were terminated by addition of an equal volume 
of 2× sample buffer. The TGF-β receptor kinase activity was analyzed 
by SDS-PAGE and immunoblotting with anti-phosphotyrosine mono-
clonal antibody 4G10 and anti-Flag antibody.
ALK5/TβRI catalytic domain kinase assay. ALK5/TβRI kinase assays 
using purified catalytic domain were performed by Reaction Biology 
Corp. The reaction buffer contained 20 mM HEPES, pH 7.5, 10 mM 
MgCl2, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 
mM DTT, and 200 μM N-acetylcysteine. In brief, ten 3-fold series dilu-
tions of 3Abd and control pyrogallol or 2Abd starting at 100 μM were 
delivered into kinase reaction mixture with kinase, cofactors, and sub-
strate. After 20 minutes of incubation at room temperature, 33P-ATP was 
delivered into the mixture to initiate the reaction. Kinase activity was 
detected 2 hours later by P81 filter-binding method.
Coculture SMAD-binding element reporter. NMuMG and A549 cells 
were transiently transfected with pGL(CAGA)12Luc using Turbofect 
reagent as specified by the manufacturer (Thermo Fisher Scientific). 
The transfected cells were seeded into a 96-well plate in triplicates 24 
hours after transfection. Cocultured wells were seeded with transfected 
NMuMG cells and nontransfected A549 cells (1:5 ratio). The cells were 
pretreated with or without 1 μM corilagin, 1 μM EGCG, 10 μM 3Abd, or 
5 μM SB431542 for 6 hours before stimulation with TGF-β1 overnight. 
The cells were lysed and luciferase activity was measured using the 
luciferase assay kit (E4030) from Promega.
Quantitative reverse transcription PCR analysis. Total RNA (1 μg of 
each sample isolated using RNeasy Kit, 74004, Qiagen) was reverse 
transcribed using SuperScript III (18080-051, Invitrogen) and assayed 
for gene expression using Platinum Quantitative PCR SuperMix-UDG 
(11730-025, Invitrogen). β-Actin, Gapdh, and S9 were used as internal 
controls, and all the data were normalized by β-actin. The primer and 
probe sequences are listed in Supplemental Table 1.
Mouse lung cell sorting and analysis. Mouse lung single-cell prepa-
rations were performed as previously described (57). Single cells were 
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